



PATIENT START FORM

TZIELD® (teplizumab-mzwv) Injection 2 mg/2 mL

Please sign, date, and fax the form to 908-425-4840 Form must be submitted by prescriber's office only

For more information about **Provention Bio COMPASS**. call 1-844-778-2246 Monday through Friday, 8 AM-8 PM ET.

Provention Bio COMPASS aims to provide confirmation of receipt within 24 hours of receiving this enrollment. If you do not receive confirmation of receipt, please call Provention Bio COMPASS.

*Indicates required field.						
1 PATIENT INFORMATION	N					
☐ *I certify that as the prescriber, I have eng	aged in a comprehens	ive discussion about th	e therapy w	vith the patient, and	I the patient has given their con	sent to begin treatment.
*Patient First Name:	*Patient Last	Name:		*Sex Assigned		th:/
*Patient Address:		*	City:		☐ Female * State :	*ZIP:
*Primary Phone # (leave blank if patient is un	der 18 years old):		Email (leave	blank if patient is u	ınder 18 years old):	
Preferred Form of Communication: Phone Text Email Do no		Time to Contact: 🖵 Mor 🖵 Afte 🗀 Nigl	ernoon	Preferred I	Language: 🖵 English 🖵 Spanish 🗖 Other	
Guardian/Caregiver information is required	for patients under 18	3 years old (leave blar	nk if patient	is over 18 years o	ld):	
*Guardian/Caregiver Name:				*Relationship	to Patient:	
*Guardian/Caregiver Primary Phone #:				Email:		
Secondary Caregiver Name:				Relationship t	to Patient:	
Secondary Caregiver Primary Phone #:				Email:		
2 INSURANCE INFORMA	TION					
*Primary Insurance: Patient has no insurance (proceed to Section	3)	-				
*Insurance Provider:		*Phone #:		*Policy ID #:	*Group #: _	
*Policy Holder Name:		*Policy Holder Date o	f Birth:		_ *Policy Holder Relationship to	Patient:
*RxBIN #: *PCN #:						
Secondary Insurance:						
Insurance Provider:		Phone #:		Policy ID #:	Group #: _	
Policy Holder Name:		Policy Holder Date of	Birth:	//	Policy Holder Relationship to	Patient:
Dloseo Soloct Acquisition Mothod:	ited specialty pharma ialty Distributor: ialty Pharmacy: io	cies. Actual dispensing Cardinal Specialty Distril	<i>method ma</i> oution	y be specified by th	ption form. ne patient's insurance. rmacy Solutions 🔲 No preferen	ce 🗖 Unsure
*Clinic Name:	*First Name:		*Last Na	me:		
*Prescriber NPI:	*Prescriber Tax ID:		*Address	5:		
*City:	*State: *ZIP:	:	*Office C	Contact Name:		
*Office Contact Phone #:	*Fax #:	*Office Contact	t Email:			
4 INFUSION SITE OF CAR	RE INFORMATION	ON				
☐ I have discussed infusion site of care prefe☐ I would like assistance from Provention Bic☐ I will provide infusion site information. Pati☐ Prescriber's office (SECTION 3)☐ At home with a nurse (same address as☐ Infusion facility (please list on next page)	COMPASS to advise or ent will be infused at: SECTION 1; if different,	n an infusion site. list on next page)	Both facility	and home. Please	indicate the number of doses to usion site below: days	be infused to be infused at facility to be infused at home

Inferior City /if	atient in striume.	*Date of Birth:/			
Intusion Site (If unknown, Provention Bio COMPASS can suppor	rt with infusion site identification/options)				
Infusion Site Name:	Infusion Site NPI:	Tax ID #:			
Address:	City:	State: ZIP:			
Infusion Center Contact Name:	Infusion Center Contact Phone #:	Fax #:			
5 CLINICAL DIAGNOSIS					
Primary Diagnosis ICD-10 Code: 🔲 E10.9 🛄 E10.8 🛄 Other (In	clude ICD-10):				
Please indicate which tests have been conducted to confirm pati	ent's diagnosis (please attach clinical documentation of the	ese test results):			
*Confirmation of dysglycemia without overt hyperglycemia: ☐ Oral Glucose Tolerance Test (OGTT) (CPT® Code: 82951)	*Confirmation of at least 2 pancreatic islet cell autoanti ☐ Insulin autoantibody (IAA) (CPT® Code: 86337)	bodies (select positive autoantibodies below):			
☐ Fasting Plasma Glucose (FPG) (CPT® Code: 82947)	☐ Glutamic acid decarboxylase 65 (GAD) (CPT® Code: 86341)				
☐ A1C (CPT® Code: 83036)	☐ Insulinoma-associated antigen 2 autoantibody (IA-2A) (CPT® Code: 86341)				
*Glucose/A1C level:	☐ Islet cell autoantibody (ICA) (CPT® Code: 86341)				
*Date test completed:	☐ Zinc transporter 8 autoantibody (ZnT8A) (CPT® Code: 86341) *Date test completed:				
$oldsymbol{\square}$ *I certify that the patient's clinical history and associated diagr	nosis do not suggest Stage 3 type 1 diabetes (clinical sympt	toms and overt hyperglycemia).			
Please call Provention Bio COMPASS at 1-844-778-2246 Monday th Patient Allergies:		requirea tests.			
Prior/Current Medications:		ORMATION			
Prior/Current Medications:	CTION 2 mg/2 mL PRESCRIPTION INFO	DRMATION			
Prior/Current Medications: TZIELD® (teplizumab-mzwv) INJEC	CTION 2 mg/2 mL PRESCRIPTION INFO	DRMATION m² *Date Measured:			
Prior/Current Medications: TZIELD® (teplizumab-mzwv) INJEC Infuse according to the body surface area-based dosing regime *Patient Height: *Patient Weight:	CTION 2 mg/2 mL PRESCRIPTION INFO				
TZIELD® (teplizumab-mzwv) INJEC Infuse according to the body surface area-based dosing regime	en in the Prescribing Information for TZIELD. *Body Surface Area (BSA): Calculate using the Mostellar formula BSA:				
Prior/Current Medications: TZIELD® (teplizumab-mzwv) INJEC Infuse according to the body surface area-based dosing regime *Patient Height: *Patient Weight: *Quantity to Dispense:	en in the Prescribing Information for TZIELD. *Body Surface Area (BSA): Calculate using the Mostellar formula BSA: ≤ 1.94 m²				
Prior/Current Medications: TZIELD® (teplizumab-mzwv) INJEC Infuse according to the body surface area-based dosing regime *Patient Height: *Patient Weight: *Quantity to Dispense: 14 TZIELD 2 mg/2 mL, single-dose via 24 TZIELD 2 mg/2 mL, single-dose via	TION 2 mg/2 mL PRESCRIPTION INFO en in the Prescribing Information for TZIELD. *Body Surface Area (B5A): Calculate using the Mostellar formula B5A: ≤ 1.94 m² > 1.94 m²	m ² *Date Measured:			
TZIELD® (teplizumab-mzwv) INJEC Infuse according to the body surface area-based dosing regime *Patient Height: *Quantity to Dispense: 14 TZIELD 2 mg/2 mL, single-dose via 24 TZIELD 2 mg/2 mL, single-dose via Refills: No refills	TION 2 mg/2 mL PRESCRIPTION INFO en in the Prescribing Information for TZIELD. *Body Surface Area (B5A): Calculate using the Mostellar formula B5A: ≤ 1.94 m² > 1.94 m²	m ² *Date Measured:			

By signing above, I certify that (1) the information contained in this application is current, complete, and accurate to the best of my knowledge; (2) the above therapy is medically necessary and in the best interest of the patient identified above and that I will supervise the patient's treatment accordingly; (3) I have obtained any consent required under federal and state law for the release and use of the patient's personal health information including diagnosis, treatment, medical, and insurance information contained on this form to Provention Bio and its agents, service providers, and affiliates, including commercial and field-based teams, for purposes of benefits verification and coordination of dispensing therapy, or to otherwise assist the patient to initiate or continue the prescribed therapy and/or to evaluate the patient's eligibility for Provention Bio COMPASS or other programs for TZIELD; and (4) I will not seek payment from any payer, patient, or other source for free product provided directly to the patient. I have obtained patient's permission to enroll them in Provention Bio COMPASS and for them to be contacted by Provention Bio in connection with this application.

I understand that I am under no obligation to prescribe any Provention Bio therapies or to participate in Provention Bio COMPASS, and that I have not received, nor will I receive, any benefit from Provention Bio for prescribing a Provention Bio therapy. I certify that I am a legal resident of the United States (and US territories).

I authorize Provention Bio and its agents to convey the above prescription by any means allowed under applicable law to the dispensing pharmacy.

Before prescribing TZIELD, please read the accompanying Prescribing Information, including Medication Guide.



